Pancreatic Cancer Research

Clinical trialPhase 2Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
28 April 2017
Ended
21 December 2022
Enrollment
13 participants
Sites
405
Primary outcomes
Overall Response Rate
Sponsor type
NIH
Results posted
5 April 2022
Last update
17 October 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 17 October 2023
ORR
Overall Response RateArm A (MLN0128): 0 (0 to 0.26), n = 12Values: proportion of participants, 95% Confidence IntervalTime frame: Assessed every 3 months for the first 2 years, every 6 months for the 3rd year, then annually up to 5 yearsNo analysis posted for this outcome (outcome 1)
Participants
Arm A (MLN0128): 13 started, 0 completed
Serious adverse events
Arm A (MLN0128): 7 of 13Participants with at least one serious adverse event, of those at risk, as posted
3 secondary outcomes, the first 2 shown
PFS · Progression-free Survival (PFS)
Arm A (MLN0128) 5.19 (3.84 to 9.3), n=12 [median months, 95% Confidence Interval]
DCR · Disease Control Rate
Arm A (MLN0128) 0.67 (0.35 to 0.90), n=12 [proportion of participants, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVE: I. To evaluate overall response rate associated with sapanisertib (MLN0128 \[TAK-228\]) in patients with advanced pancreatic neuroendocrine tumors (PNETs). SECONDARY ENDPOINTS: I. To evaluate progression-free survival (PFS) associated with MLN0128 (TAK-228) in patients with advanced pancreatic neuroendocrine tumors (PNETs). II. To measure the safety and tolerability of MLN0128 (TAK-228) in patients with advanced PNETs. III. To evaluate disease control rate associated with MLN0128 (TAK-228) in patients with advanced PNETs. IV. To measure duration of response rate associated with MLN0128 (TAK-228) in patients with advanced PNETs. OUTLINE: Patients receive sapanisertib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 1 year, and then yearly for 2 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Overall Response Rate [Assessed every 3 months for the first 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Number, proportion of participants (95% Confidence Interval). Arm A (MLN0128) (n=12): 0 (0 to 0.26).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Median, months (95% Confidence Interval). Arm A (MLN0128) (n=12): 5.19 (3.84 to 9.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control Rate [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Number, proportion of participants (95% Confidence Interval). Arm A (MLN0128) (n=12): 0.67 (0.35 to 0.90).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years].